

# 1 Probiotic effect of trichloroacetic acid 2 on cervicovaginal microbiota in 3 cervical intraepithelial neoplasia: A 4 pilot study

5 Takeo Shibata<sup>1</sup>, Ayumu Ohno<sup>2,5,6</sup>, Isao Murakami<sup>3</sup>, Masahiro Takakura<sup>1</sup>, Toshiyuki  
6 Sasagawa<sup>1\*</sup>, Tadashi Imanishi<sup>2</sup>, Mikio Mikami<sup>4</sup>

**\*For correspondence:**

[tsasa@kanazawa-med.ac.jp](mailto:tsasa@kanazawa-med.ac.jp) (TS)

**Present address:** \*Department of  
Obstetrics and Gynecology,  
Kanazawa Medical University, 1-1  
Daigaku, Uchinada, Ishikawa  
920-0293, Japan

7 <sup>1</sup> Department of Obstetrics and Gynecology, Kanazawa Medical University, 1-1 Daigaku,  
8 Uchinada, Ishikawa, Japan ; <sup>2</sup> Department of Molecular Life Science, Tokai University  
9 School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan ; <sup>3</sup> Department of  
10 Obstetrics and Gynecology, Toho University Ohashi Medical Center, 2-22-36 Ohashi,  
11 Meguro, Tokyo, Japan ; <sup>4</sup> Department of Obstetrics and Gynecology, Tokai University  
12 School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan ; <sup>5</sup> Graduate School of  
13 Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1  
14 Tsushima-naka, Kita-ku, Okayama, Okayama, Japan ; <sup>6</sup> Collaborative Research Centre of  
15 Okayama University for Infectious Diseases in India at ICMR-NICED, 57 Dr. SC Banerjee  
16 Road, Beliaghata Kolkata, India

---

18 **Abstract** Symbiosis of bacteria and human papillomavirus (HPV) in the cervicovaginal  
19 environment influences cervical intraepithelial neoplasia (CIN) progression or regression. In this  
20 case series, we enrolled all 10 patients who had resolved CIN after a cervical local treatment using  
21 trichloroacetic acid (TCA). Prominent changes in the cervicovaginal microbiota, such as an  
22 enrichment of the genus *Bifidobacterium* and genus *Lactobacillus*, were observed in seven of 10  
23 patients. A decrease in cervicovaginal bacterial alpha diversity was observed in 4 patients with  
24 high-risk HPV clearance. Differential abundance analysis revealed that genus *Bifidobacterium*  
25 increased significantly after TCA. The dominance of a single bacteria can be characteristic of CIN  
26 cures after TCA. These results highlight the potential link of cervicovaginal bacteria such as genus  
27 *Bifidobacterium* and genus *Lactobacillus* in the clearance of CIN and high-risk HPV. This pilot study  
28 guides future research questions that specific cervicovaginal bacteria may be promising candidates  
29 for probiotic therapy to treat CIN and HPV infections.

---

## 31 Introduction

32 About 5% of all cancers are attributed to human papillomavirus (HPV) infection *Forman et al. (2012)*.  
33 HPV infects mucous membranes and causes a variety of diseases such as genital warts, precancerous  
34 cervical lesions (cervical intraepithelial neoplasia: CIN), cervical cancer, vaginal intra-epithelial  
35 neoplasia (VAIN), vaginal cancer, vulvar cancer, penile cancer, anal cancer, head and neck cancer,  
36 and even recurrent respiratory papillomatosis throughout the body *Doorbar et al. (2015) WHO (2021)*.  
37 HPVs are classified into more than 200 genotypes, some HPVs are categorized based on the risk of  
38 developing cancer, such as high-risk HPV (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,

39 and 68) *Doorbar et al. (2012)* *Hum (2021b)*. Especially, HPV type 16 or HPV type 18 causes 70% of  
40 cervical cancers and CIN *Hum (2021a)*. The development of HPV-related diseases, namely CIN and  
41 cervical cancer, has been elucidated in considerable detail in molecular biology *Doorbar et al. (2012)*.  
42 E6 and E7 proteins as viral oncogenes and proteins are key to carcinogenesis. They modulate the  
43 activity of p53 and retinoblastoma family proteins *Doorbar et al. (2012)*.

44 The factors that influence the progression or regression of CIN are unknown, however, HPV  
45 is the evident cause of CIN *Sasagawa et al. (1992)* and cervical cancer *Pal and Kundu (2020)*. HPV  
46 infection is a common infection that affects more than half of the cases within 5 years of the onset  
47 of sexual intercourse *Winer et al. (2003)*. However, the incidence of cancer is low compared to  
48 the infection rate of HPV *Winer et al. (2003)*. Evidence suggests an association between symbiotic  
49 bacteria in humans and carcinogenesis *Doocey et al. (2022)*. The cervicovaginal bacterial community  
50 have been shown to be associated with the progression or elimination of CIN or HPV infection *Mitra*  
51 *et al. (2016)* *Kyrgiou et al. (2017)* *Norenhag et al. (2020)* *Lin et al. (2020)* *Cheng et al. (2020)* *Usyk et al.*  
52 *(2020)*. As a feature of cervical or vaginal microbiome (cervicovaginal microbiome), *Lactobacillus* are  
53 dominant, however, non-*Lactobacillus*-dominance or *Lactobacillus iners* are dominant in the patients  
54 with CIN or high-risk HPV positive *Norenhag et al. (2020)* *Lin et al. (2020)*. Non-*Lactobacillus*-dominant  
55 environment such as bacterial vaginosis (BV) was associated with higher rates of HPV infection, high-  
56 risk HPV persistence, and delayed HPV clearance *Kyrgiou et al. (2017)*. In particular, cervicovaginal  
57 bacterial composition under HPV infection was characterized by BV-associated bacteria, which is an  
58 anaerobic bacteria such as *Sneathia*, *Prevotella*, and *Megasphaera* *Cheng et al. (2020)*. In addition,  
59 *Gardnerella*-enrichment is associated with developing high-grade squamous intraepithelial lesion  
60 (HSIL) in a longitudinal study *Usyk et al. (2020)*. Multiple HPV infections compared to no HPV  
61 infections were attributed to the increased bacterial biodiversity (i.e., high alpha diversity) *Cheng*  
62 *et al. (2020)*.

63 A classic excision procedure called cervical conization for CIN, which removes the cervix, has  
64 been reported to increase Obstetric adverse events such as preterm birth and premature rupture  
65 of membranes *Bevis and Biggio (2011)*. To develop minimally invasive treatment, we conducted  
66 clinical trials for trichloroacetic acid (TCA) or phenol treatment on the CIN or VAIN lesions *Maehama*  
67 *et al. (2023)*. In phenol-treated patients, disease regression rates after 24 months for CIN1-3  
68 were 99%, 98%, and 100%, respectively *Maehama et al. (2023)*. We observed that most patients  
69 resolved CIN or VAIN lesions upon TCA application within one year (in preparation). This chemical  
70 peeling method presumes to remove the epithelial lesions of such HPV-related diseases. The host  
71 immune responses are likely to be involved with the complete clearance of diseases by this method.  
72 TCA treatment can potentially avoid cervical conization and hysterectomy and is a more desirable  
73 treatment for women who wish to bear children in the future.

74 We hypothesize that cervicovaginal bacterial dynamics are involved with the clearance of CIN and  
75 HPV infection after TCA treatment. In this pilot study, we investigated the difference in cervicovaginal  
76 bacteria before and after chemical peeling treatment by TCA in patients who had cleared not only  
77 CIN/VAIN but also high-risk HPV with TCA treatment. We attempt to identify bacteria that are  
78 candidates for probiotic treatment to establish safe and effective invasive treatment for CIN or  
79 VAIN.

## 80 Results

### 81 Patient characteristics and clearance of HPV

82 The average age of patients enrolled in this pilot study was  $35.7 \pm 8.1$  years old (10 patients). The  
83 average TCA treatment duration of patients with CIN or VAIN lesions from initial sample collection to  
84 eventual cure was 289 days. The 10 patients with CIN (nine patients: one CIN1; two CIN2; six CIN3) or  
85 VAIN (one patient, VAIN2) diagnosed by colposcopy and biopsy were enrolled in this analysis (Table  
86 1). The distribution of race or ethnicity was 100% Japanese. In pre- TCA treatment phase, cervical  
87 cytology was; atypical glandular cells: AGC (n = 1), adenocarcinoma in situ: AIS (n = 1), atypical

88 squamous cells of undetermined significance: ASCUS (n = 1), high grade squamous intraepithelial  
89 lesion: HSIL (n = 4), and low grade squamous intraepithelial lesion: LSIL (n = 3). High-risk HPV was  
90 90% positive before TCA treatment and 60% after TCA treatment (Table 1). However, at follow-up  
91 after TCA treatment we observed that high-risk HPV disappeared in all patients within 9 months  
(Table 2).

**Table 1.** Patient Characteristics.

Test	Diagnosis	Number of Patients	Frequency (%)
Before Treatment			
Cytology	AGC	1	10
	AIS	1	10
	ASCUS	1	10
	HSIL	4	40
	LSIL	3	30
Biopsy	CIN1	1	10
	CIN2	2	20
	CIN3	6	60
	VAIN2	1	10
High-risk HPV*	Negative	1	10
	Positive	9	90
After Treatment			
Cytology	NILM	10	100
High-risk HPV*	Negative	4	40
	Positive	6	60

\*: Total 14 high-risk HPV genotypes were defined as HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. AGC: atypical glandular cells; AIS: adenocarcinoma in situ; ASUCUS: atypical squamous cells of undetermined significance; HSIL: high grade squamous intraepithelial lesion; LSIL: low grade squamous intraepithelial lesion; CIN: cervical intraepithelial neoplasia; VAIN: vaginal intraepithelial neoplasia; HPV: human papillomavirus; NILM: negative for intraepithelial lesion or malignancy.

92

### 93 **Statistics of reads and taxa**

94 After importing 20 raw fastq files, we obtained a total of 1,812,889 reads, mean 90644.4 reads,  
95 median 83714.5 reads, minimum 6658 reads, and maximum 191,622 reads. After final quality  
96 filtering using q2-dada2 and q2-quality-control, we obtained 494 features (taxa) and a total of  
97 714,869 features (taxa) in 20 samples. For read-length, the minimum length was 38, maximum  
98 length 283, and mean length 236.96.

### 99 **Characteristics of cervicovaginal microbiota pre- or post- TCA treatment**

100 Among the identified bacteria, the top genera before and after TCA treatment are shown in Figure  
101 1A. These top bacteria are mentioned below based on their frequency (%).

- 102 1. Genus *Lactobacillus*, after TCA, 38.9%
- 103 2. Genus *Lactobacillus*, before TCA, 37.3%
- 104 3. Genus *Gardnerella*, before TCA, 21.9%
- 105 4. Genus *Bifidobacterium*, after TCA, 16.4%
- 106 5. Genus *Prevotella*, before TCA, 12.9%
- 107 6. Genus *Gardnerella*, after TCA, 11.4%
- 108 7. Genus *Prevotella*, after TCA, 11.1%

**Table 2.** Clearance of HPV after TCA treatment.

Cases	Diagnosis	HPV Before TCA	HPV After TCA	HPV at Follow-up After TCA
Case 01	CIN3	52	67	Not examined*
Case 02	CIN3	16	66	Negative
Case 03	CIN2	6, 16, 53, 54, 58, 66	Negative	Negative
Case 04	CIN2	31	31, 51	Negative
Case 05	CIN1	51, 82	Negative	Not examined*
Case 06	VAIN2	6, 62, 81	59	Negative
Case 07	CIN3	16, 51, 56, 59, 66, 70	59	Negative
Case 08	CIN3	16	52, 67	Negative
Case 09	CIN3	16, 52	58	Negative
Case 10	CIN3	16, 31	Negative	Not examined*

\*: No HPV typing was done at the time of follow-up for patients who were negative for high-risk HPV after TCA treatment. HPV: human papillomavirus; TCA: trichloroacetic acid; CIN: cervical intraepithelial neoplasia; VAIN: vaginal intraepithelial neoplasia.


- 109 8. Genus *Megasphaera*, before TCA, 7.14%
- 110 9. Genus *Atopobium*, before TCA, 6.87%
- 111 10. Genus *Atopobium*, after TCA, 4.19%
- 112 11. Genus *Megasphaera*, after TCA, 3.64%

113 The frequency of the top bacteria, except for genus *Bifidobacterium* did not largely change before  
114 and after TCA treatment, for example, genera *Lactobacillus* (37.3% before vs. 38.9% after TCA  
115 treatment), *Gardnerella* (21.9% before vs. 11.4% after TCA treatment), *Prevotella* (12.9% before  
116 vs. 11.1% after TCA treatment), *Atopobium* (6.87% before vs. 4.19% after TCA treatment), and  
117 *Megasphaera* (7.14% before vs. 3.64% after TCA treatment). Contrarily, the genus *Bifidobacterium*  
118 changed significantly before and after TCA treatment; the frequency increased from 1% before TCA  
119 treatment to 16.4% after TCA treatment. Figure 1B shows the change in the cervicovaginal bacterial  
120 microbiota before and after TCA treatment for each patient. Figure 1B provides information on high-  
121 risk HPV clearance and persistence after TCA treatment. An enrichment of genus *Bifidobacterium*  
122 and genus *Lactobacillus* were observed in seven of 10 patients (Cases 01, 03, 04, 05, 06, 09, and  
123 10) after TCA treatment. We found that genus *Bifidobacterium* (blue bar) increased in two patients  
124 (Cases 05 and 09) after TCA treatment. As an additional finding, in four patients (Cases 01, 03, 04,  
125 and 06), cervicovaginal bacterial microbiota was dominated primarily by the genus *Lactobacillus*  
126 (green bar, 99.9%, 100%, 98.2%, and 72.0%, respectively) after TCA treatment.

### 127 **Alpha and beta diversity analyses**


128 Decline in alpha diversity was observed in seven of 10 patients (Cases 01, 03, 05, 06, 07, 09, and 10.  
129 Figure 2). Alpha diversity was consistently decreased in four patients with high-risk HPV clearance  
130 after TCA treatment (Cases 01, 03, 05, and 10, top panel of Figure 2). Both decreased alpha diversity  
131 (three patients, Cases 06, 07, and 09) and increased (three patients, Cases 02, 04, and 08) were  
132 observed in patients with high-risk HPV persistence after TCA treatment (bottom panel of Figure 2).

133 We examined whether the cervicovaginal bacterial microbiota is affected by factors including;  
134 factor 1: individuals, factor 2: pre- or post-TCA treatment, and factor 3: high-risk HPV. Individual  
135 differences, not TCA treatment or high-risk HPV, define the similarity of bacterial composition in the  
136 cervicovaginal bacterial microbiota (Figure 3). About 50.9% of microbial variation could be explained  
137 by patient differences ( $R^2 = 0.509$ ,  $p = 0.030$ , Adonis test, Figure 3A). High-risk HPV infection before  
138 TCA treatment explained 6.8% variation of microbe composition ( $R^2 = 0.068$ ,  $p = 0.149$ , Adonis  
139 test, Figure 3C). High-risk HPV infection after TCA treatment explained 6.7% variation of microbe  
140 composition ( $R^2 = 0.067$ ,  $p = 0.131$ , Adonis test, Figure 3D). Before and after chemical peeling using



**Figure 1. Characteristics of cervicovaginal microbiota before and after TCA treatment for CIN/VAIN. A:** The relative abundance of taxa before and after TCA treatment is shown on the x-axis and the top 10 bacteria at the genus level are plotted in colored bar plots. **B:** The relative abundance of taxa is displayed for each patient, before and after TCA treatment, and with high-risk HPV clearance information after TCA treatment. TCA: trichloroacetic acid; ASV: amplicon sequence variant; HPV: human papillomavirus.

141 TCA explained only 3.6% variation of microbe composition ( $R^2 = 0.036$ ,  $p = 0.408$ , Adonis test, Figure  
142 3B).



**Figure 2. Analysis of alpha diversity before and after TCA treatment.** Alpha diversity is reduced in high-risk HPV-negative cases, whereas alpha diversity is variable in high-risk HPV-positive cases. Alpha diversity was consistently decreased in four patients with high-risk HPV clearance after TCA treatment (Cases 01, 03, 05, and 10, top panel). In patients with high-risk HPV persistence after TCA treatment (bottom panel), both decreased alpha diversity (Cases 06, 07, and 09) and increased (Cases 02, 04, and 08) were observed.


143 **Differential abundance analysis for cervicovaginal microbiota between pre- and**  
144 **post-TCA**

145 There was a remarkable increase in genus *Bifidobacterium* in Cases 05 and 09 after TCA treatment,  
146 as shown in the bar graphs (Figure 1B). Consistent with this result at the genus level, we observed  
147 an increase in one *Bifidobacterium sp.* after TCA treatment, although we were unable to identify  
148 the species due to the resolution limitation of 16S rRNA analysis (log fold-change:  $-25.0$ , adjusted  
149 p-value  $< 0.001$ , Figure 4). Results for the genus *Lactobacillus* and *Lactobacillus sp.* were inconsistent  
150 between pre- and post-TCA treatment. Thus, some *Lactobacillus* species were enriched after TCA  
151 treatment, while others were before TCA treatment. The *Lactobacillus sp.* enriched before TCA  
152 treatment were not identified due to the resolution limitation of 16S rRNA analysis (log fold-change:  
153  $23.1$ , adjusted p-value  $< 0.001$ , Figure 4).

154 **Discussion**

155 Nonsurgical treatment of CIN should be especially considered for women of childbearing age. The  
156 effectiveness of TCA treatment for CIN has been analyzed not only by us but also by multiple research  
157 groups, and it may become a standard treatment for CIN in the future *Schwameis et al. (2022)*.  
158 However, there is a lack of data regarding the healing mechanism of CIN after TCA treatment. As  
159 represented in *Döderlein's bacillus* described by Dr. Albert Döderlein, a relatively simple composition  
160 of bacteria such as *Lactobacillus* in the vagina is healthy. Persistent HPV infection increases the risk  
161 of developing cervical cancer and CIN; however, it is unclear what type of cervicovaginal bacteria  
162 are involved in the disappearance of CIN. This research is an attempt to analyze the relationship  
163 between cervicovaginal microbiota, high-risk-HPV, and the regression of CIN.


164 In this study, the mean duration required for the clearance of CIN or VAIN lesions after TCA  
165 administration was 289 days. After nearly a year of long-term follow-up along with high risk-HPV  
166 disappearance, it was observed that the cervicovaginal microbiota in CIN/VAIN-cured patients



**Figure 3. Principal component analysis (beta diversity) by patients, TCA treatment, and high-risk HPV.**

Samples are predominately clustered by (A) individuals. Samples are not clustered by (B) pre- or post-TCA treatment, (C) high-risk HPV infection before TCA treatment, and (D) high-risk HPV infection after TCA treatment. A: Samples are colored with 10 kinds of color for each patient. B: Samples are colored by after TCA treatment (red, diamond) and before TCA treatment (blue, circle). C: Samples before TCA treatment are colored by high-risk HPV positive (green, circle) and negative (purple, diamond). D: Samples after TCA treatment are colored by high-risk HPV positive (green, circle) and negative (purple, diamond). About 50.9% of microbial variation could be explained by patient differences ( $R^2 = 0.509$ ,  $p = 0.030$ , Adonis test, A). Before and after chemical peeling using TCA explained only 3.6% variation of microbe composition ( $R^2 = 0.036$ ,  $p = 0.408$ , Adonis test, B). High-risk HPV infection before TCA treatment explained 6.8% variation of microbe composition ( $R^2 = 0.068$ ,  $p = 0.149$ , Adonis test, C). High-risk HPV infection after TCA treatment explained 6.7% variation of microbe composition ( $R^2 = 0.067$ ,  $p = 0.131$ , Adonis test, D).





**Figure 4. Enriched taxa pre- and post-TCA.** *Bifidobacterium sp.* was detected in enriched taxa after TCA treatment (log fold-change: -25.01414, p-value: 2.687858e-17, adjusted p-value: 9.649411e-15). *Lactobacillus sp.* was detected in enriched taxa before TCA treatment (log fold-change: 23.06017, p-value: 6.417715e-15, adjusted p-value: 1.151980e-12)

167 changed into an environment dominated largely by a single bacteria such as genus *Lactobacillus*  
168 or *Bifidobacterium* (Figure 1). Then, BV-associated bacteria such genera *Gardnerella*, *Prevotella*,  
169 *Atopobium*, and *Megasphaera* were decreased after TCA treatment (Figure 1). A simplification of  
170 the bacterial composition, suggested by a decrease in alpha diversity was observed in all patients  
171 with all CIN clearance and high-risk HPV negative, whereas an increase in alpha diversity was seen  
172 in patients with persistent HPV, suggesting that the cervicovaginal microbiome may influence the  
173 action of high-risk HPV elimination (Figure 2). The enrichment of *Bifidobacterium sp.* after TCA  
174 treatment in the patients with CIN or VAIN clearance is enough to be detected by differential  
175 abundance analysis, suggesting that the transformation into a single microbiota in the cervix and  
176 vagina, not only by *Lactobacillus* but also by *Bifidobacterium* may be the key to clearance of CIN  
177 or VAIN lesions (Figure 4). Taken together, this study infers the natural history of CIN clearance  
178 processes with TCA treatment associated with high-risk-HPV and the cervicovaginal microbiome.  
179 Thus, below is a possible mechanism by which TCA treats CIN; TCA first causes detachment of the  
180 CIN/VAIN lesion (phase I), changes in the cervicovaginal microbiome (phase II, increase in genera  
181 *Lactobacillus* and *Bifidobacterium* and decrease in BV-associated bacteria), clearance of high-risk-HPV  
182 (phase III).

183 We should be cautious about whether *Bifidobacterium* could be a candidate for probiotic treat-  
184 ment of CIN and HPV infections. However, previous studies suggest that *Bifidobacterium* is a useful  
185 bacterium against HPV infection. Mei et al. reported that *Bifidobacterium* were enriched in the  
186 patients with clearance of HPV 16 compared to patients with no history of high risk-HPV infection **Mei**  
187 **et al. (2022)**. Similarly, this phenomenon was observed in Case 09 (i.e., HPV16 was negative at  
188 follow-up after TCA treatment). Cha et al. reported the probiotic effect of *Bifidobacterium* on SiHa  
189 cervical cancer cell line expressing HPV 16 and found the suppression of E6 and E7 **Cha et al. (2012)**.  
190 Further investigation is needed to decipher the relationship between *Bifidobacterium* and CIN and  
191 HPV persistent/clearance.

192 When discussing whether *Lactobacilli* affects the clearance of CIN and HPV, we should discuss it  
193 at the species level rather than the genus level. Ou et al. reported the effects of oral administration  
194 of *Lactobacillus rhamnosus* and *Lactobacillus reuteri* on HPV clearance and cervical cytology: rate  
195 of ASCUS and LSIL dropped from 21.0% to 6.5% in probiotic group vs 15.3% to 10.2% in control  
196 group,  $p = 0.017$  **Ou et al. (2019)**. According to Nicolò et al., *Lactobacillus gasseri* or *Lactobacillus*  
197 *jensenii* induce interferon- $\gamma$  and these species may have the potential to assist immune cells with  
198 HPV clearance **Nicolò et al. (2021)**. On the contrary, Brotman et al. showed that *Lactobacillus iners*  
199 had relatively higher proportion of HPV-positive samples, suggesting their link with the risk of HPV  
200 persistence **Brotman et al. (2014)**. In this study, an increase in genus *Lactobacillus* was observed after  
201 CIN cure (Figure 1), but upon differential abundance analysis, *Lactobacillus sp.* decreased (Figure  
202 4). That is, some *Lactobacillus spp.* increased before TCA treatment, while other *Lactobacillus spp.*  
203 decreased after TCA treatment. Analysis using long reads is necessary to identify the abundance at



204 species level.

205 However, there are certain limitations of this study. In this case series, we analyzed only 10  
206 patients with cured CIN, with emphasis on the homogeneity of the patient background. It is difficult  
207 to draw general conclusions from case series, therefore, in the next project that expands on this  
208 research, we plan to conduct a case-control study and time-series analysis of a large number of  
209 healthy women as well as CIN patients receiving TCA treatment. Their use in probiotic therapies for  
210 CIN require detailed basic microbiological studies and prospective clinical trials that were beyond  
211 the scope of this study. A clear understanding of the interplay between several factors, including  
212 oncogenic HPV, humans, bacteria, and possibly a fungus in order to control probiotic treatment  
213 that manipulates the composition of cervicovaginal bacteria is necessary.

214 The cervicovaginal microbiome is an important factor in the clearance of CIN and HPV. Low inva-  
215 sive local treatment with chemical peels using TCA may be associated with changes in *Lactobacillus* or  
216 *Bifidobacterium* in the cervicovaginal microbiota. This pilot study leads to the hypothesis that certain  
217 bacteria that fluctuate in the cervicovaginal ecology are promising as they may be prospective  
218 candidates for probiotic treatment to treat CIN and HPV infection. We advocate the importance of  
219 CIN management in order to understand not only the state of oncogenic HPV infection but also  
220 the cervicovaginal microbiome. Further intensive research in metabolome or immunity research is  
221 needed to examine both the role of the cervicovaginal microbiota in cancer and the use of probiotics  
222 for cancer treatment.

## 223 **Methods and Materials**

### 224 **Ethics approval**

225 This study was approved by the Institutional Review Board at the Kanazawa Medical University (IRB  
226 #I322). Written informed consent was obtained from all study patients.

### 227 **Patient selection and chemical peeling treatment with TCA for CIN and VAIN**

228 Eligible patients who met the following conditions were selected for this pilot study; 1: Patients  
229 treated by TCA at Kanazawa Medical University during the period from 2017 to 2020; 2: A cytology  
230 specimen prior to TCA treatment was archived; 3: All patients were those who were cleared with  
231 CIN or VAIN after TCA treatment. Under the above selection conditions, 14 patients were treated  
232 with TCA, 12 patients had samples available, and 10 patients with cured CIN or VAIN lesions were  
233 included in the analysis. All 10 patients were diagnosed with CIN or VAIN using the punch biopsy  
234 specimens under the guidance of colposcopy. No patients have undergone a hysterectomy or loop  
235 electrosurgical excision procedure (LEEP) before or after TCA treatment. TCA (70%) was applied to  
236 wide areas of the cervical or vaginal lesions three to five times using a small cotton tip every 4 weeks.  
237 The Pap test using the liquid-based cytology (LBC) sample was performed in all patients every visit  
238 at 4 weeks intervals until disease clearance. Confirmation of CIN and VAIN lesion disappearance in  
239 colposcopy after Pap test-negative (i.e., negative for intraepithelial lesion or malignancy: NILM) was  
240 the definition of disease clearance. We examined cervicovaginal microbiota in the LBC samples  
241 before (CIN/VAIN lesion persistence) and after (CIN/VAIN lesion clearance) TCA treatment in this  
242 study.

### 243 **HPV genotyping**

244 HPV-DNA was detected by Uniplex E6/E7 PCR method or GENOSEARCH™ HPV 31 (Medical & Biological  
245 Laboratories, Co., Ltd., Tokyo) which can detect up to 39 or 31 HPV genotypes each using LBC  
246 samples (ThinPrep solution, HOLOGIC, Marlborough, MA USA) *Okodo et al. (2018)*. A total of 14  
247 types including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were classified as high-risk  
248 HPV genotypes *Campos-Romero et al. (2019)*. HPV genotyping was performed for the samples at 1:  
249 before TCA treatment, 2: after TCA treatment, and 3: follow-up after TCA treatment.

## 250 **DNA extraction and 16S ribosomal RNA gene sequencing**

251 LBC samples were sent to Tokai University (Isehara, Japan) for DNA extraction, amplification, and  
252 the 16S ribosomal RNA (rRNA) gene sequencing on an Ion PGM™ System (Thermo Fisher Scientific,  
253 Waltham, MA USA). The Ion 16S™ Metagenomics Kit was used. Single-end reads were generated for  
254 the seven hypervariable regions (V2, V3, V4, V6, V7, V8, and V9)*Barb et al. (2016)*.

## 255 **Microbiome analysis**

256 Microbiome bioinformatics was performed with R (version 4.2.1) and QIIME2-2020.11 *Bolyen et al.*  
257 *(2019)*. Hereafter, the abbreviation q2- means QIIME 2 plugins and r- R packages. The Taxonomy  
258 database was built using q2-RESCRIPT and SILVA rRNA gene database (SILVA138.1)*Robeson et al.*  
259 *(2021)**Quast et al. (2012)*. We removed low-quality sequences, such as those containing five or more  
260 ambiguous bases and eight or more homopolymers. We adopted bacteria rRNA gene sequences  
261 over 1400 bp to build the taxonomy database *Robeson et al. (2021)**Yang et al. (2016)*. Naive-Bayes-  
262 based taxonomy classifier was created through q2-feature-classifier *Bokulich et al. (2018)**Pedregosa*  
263 *et al. (2011)**Ziemski et al. (2021)*.

264 Demultiplexed 20 fastq files for samples before and after chemical peeling by TCA of 10 patients  
265 consisting of single-end reads were imported by q2-tools import command and visualized by q2-  
266 demux summarize. We generated an amplicon sequence variant (ASV) using q2-dada2 *Callahan et al.*  
267 *(2016)*. The q2-dada2 denoised and dereplicated reads and removed chimeras *Callahan et al. (2016)*.  
268 Using the option of q2-dada2, the reads were trimmed at 15 bp under no truncated and pooled  
269 options *Pos (2023)*. The ASVs were assigned taxonomy through q2-feature-classifier classify-sklearn  
270 using above the Naive-Bayes-based taxonomy classifier *Bokulich et al. (2018)*. The confidence  
271 parameter in q2-feature-classifier classify-sklearn was set as 0.5 to obtain a high-recall *Bokulich*  
272 *et al. (2018)*. ASVs classified as Chloroplast, Mitochondria, Eukaryota, Unassigned and those with no  
273 phylum-level taxonomic information were removed by q2-taxa filter-table. As final quality filtering,  
274 we retained ASVs that had at least 90% identity and 90% query alignment with the SILVA ribosomal  
275 RNA gene database using q2-quality-control. The top 10 abundant taxa at the genus level were  
276 displayed in colored bar plots separated as before and after TCA treatment for each positive or  
277 negative value of high-risk HPV after TCA treatment *McMurdie and Holmes (2013)*.

278 Species richness called alpha diversity for the difference within the sample was derived using q2-  
279 breakaway *Willis and Bunge (2015)*. The changes in alpha diversity before and after TCA treatment  
280 were plotted for each patient, divided into high-risk HPV positive and negative after TCA treatment.  
281 A test of similarity called beta diversity of the cervicovaginal microbiome composition pre- or post-  
282 TCA treatment was evaluated using the q2-diversity adonis *Anderson (2001)* and plotted using the  
283 principal component analysis.

284 As differential abundance analysis for cervicovaginal microbiome before and after TCA treatment,  
285 we compared the abundance of taxa using DESeq2 in r-microbiomeMarker under the following  
286 parameter setting; normalization method: relative log expression; identity method: Wald; p-value  
287 adjustment for multiple comparisons: Benjamini-Hochberg; and p-value cutoff: 0.05 *Cao et al.*  
288 *(2022)**Love et al. (2014)*.

## 289 **Acknowledgments**

290 We would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing. We would like to  
291 thank the Medical Science College Office, Tokai University for technical assistance.

## 292 **Financial disclosure**

293 None reported.

## 294 **Conflict of interest**

295 The authors declare no potential conflict of interests.

## 296 Author contributions

297 To. S. is responsible for the study's conception and design. Ta. S. and To. S. wrote and all authors  
298 revised the manuscript. Ta. S. conducted the analyses. O. A. and T. I. conducted DNA extraction  
299 and high-throughput sequencing of DNA. All authors interpreted the data.

## 300 References

- 301 Human papillomavirus (HPV) and cervical cancer; 2021. [https://www.who.int/news-room/fact-sheets/detail/  
302 human-papillomavirus-\(hpv\)-and-cervical-cancer](https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer).
- 303 Human Papillomavirus (HPV) Infection - 2015 STD Treatment Guidelines; 2021. [https://www.cdc.gov/std/tg2015/  
304 hpv.htm](https://www.cdc.gov/std/tg2015/hpv.htm).
- 305 WHO | Human Papillomavirus; 2021. <https://www.who.int/ith/diseases/hpv/en/>.
- 306 Possible Analysis Pipeline for Ion Torrent 16S Metagenomics Kit Data in QIIME2?; 2023. <https://forum.qiime2.org>.
- 307 **Anderson MJ**. A new method for non-parametric multivariate analysis of variance. *Austral ecology*. 2001;  
308 26(1):32–46. doi: <https://doi.org/10.1111/j.1442-9993.2001.01070.pp.x>.
- 309 **Barb JJ**, Oler AJ, Kim HS, Chalmers N, Wallen GR, Cashion A, Munson PJ, Ames NJ. Development of an analysis  
310 pipeline characterizing multiple hypervariable regions of 16S rRNA using mock samples. *PLoS One*. 2016;  
311 11(2):e0148047.
- 312 **Bevis KS**, Biggio JR. Cervical conization and the risk of preterm delivery. *American journal of obstetrics and  
313 gynecology*. 2011; 205(1):19–27.
- 314 **Bokulich NA**, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Caporaso JG. Optimizing taxonomic  
315 classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. *Microbiome*.  
316 2018; 6(1):1–17.
- 317 **Bolyen E**, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar  
318 F, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nature  
319 biotechnology*. 2019; 37(8):852–857.
- 320 **Brotman RM**, Shardell MD, Gajer P, Tracy JK, Zenilman JM, Ravel J, Gravitt PE. Interplay between the temporal  
321 dynamics of the vaginal microbiota and human papillomavirus detection. *The Journal of infectious diseases*.  
322 2014; 210(11):1723–1733.
- 323 **Callahan BJ**, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference  
324 from Illumina amplicon data. *Nature methods*. 2016; 13(7):581–583.
- 325 **Campos-Romero A**, Anderson KS, Longatto-Filho A, Esparza MALR, Morán-Portela DJ, Castro-Menéndez JA,  
326 Moreno-Camacho JL, Calva-Espinosa DY, Acosta-Alfaro MA, Meynard-Mejía FA, et al. The burden of 14 hr-HPV  
327 genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional  
328 study. *Scientific reports*. 2019; 9(1):1–10.
- 329 **Cao Y**, Dong Q, Wang D, Zhang P, Liu Y, Niu C. microbiomeMarker: an R/Bioconductor package for microbiome  
330 marker identification and visualization. *Bioinformatics*. 2022; 38(16):4027–4029.
- 331 **Cha MK**, Lee DK, An HM, Lee SW, Shin SH, Kwon JH, Kim KJ, Ha NJ. Antiviral activity of Bifidobacterium adolescentis  
332 SPM1005-A on human papillomavirus type 16. *BMC medicine*. 2012; 10:1–6.
- 333 **Cheng L**, Norenhaag J, Hu YO, Brusselaers N, Fransson E, Åhrlund-Richter A, Guðnadóttir U, Angelidou P, Zha Y,  
334 Hamsten M, et al. Vaginal microbiota and human papillomavirus infection among young Swedish women.  
335 *NPJ biofilms and microbiomes*. 2020; 6(1):1–10.
- 336 **Doocoy CM**, Finn K, Murphy C, Guinane CM. The impact of the human microbiome in tumorigenesis, cancer  
337 progression, and biotherapeutic development. *BMC microbiology*. 2022; 22(1):1–17.
- 338 **Doorbar J**, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease  
339 association. *Reviews in medical virology*. 2015; 25:2–23.
- 340 **Doorbar J**, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human  
341 papillomaviruses. *Vaccine*. 2012; 30:F55–F70.

- 342 **Forman D**, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer  
343 M, et al. Global burden of human papillomavirus and related diseases. *Vaccine*. 2012; 30:F12–F23.
- 344 **Kyrgiou M**, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer?  
345 *Translational Research*. 2017; 179:168–182.
- 346 **Lin D**, Kouzy R, Abi Jaoude J, Noticewala SS, Delgado Medrano AY, Klopp AH, Taniguchi CM, Colbert LE. Microbiome  
347 factors in HPV-driven carcinogenesis and cancers. *PLoS Pathogens*. 2020; 16(6):e1008524.
- 348 **Love MI**, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.  
349 *Genome biology*. 2014; 15(12):1–21.
- 350 **Maehama T**, Shimada S, Sakamoto J, Shibata T, Fujita S, Takakura M, Takagi H, Sasagawa T. Chemical Peeling  
351 Therapy Using Phenol for the Cervico-Vaginal Intraepithelial Neoplasia. *Viruses*. 2023; 15(11):2219.
- 352 **McMurdie PJ**, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome  
353 census data. *PloS one*. 2013; 8(4):e61217.
- 354 **Mei L**, Wang T, Chen Y, Wei D, Zhang Y, Cui T, Meng J, Zhang X, Liu Y, Ding L, et al. Dysbiosis of vaginal microbiota  
355 associated with persistent high-risk human papilloma virus infection. *Journal of translational medicine*. 2022;  
356 20(1):1–8.
- 357 **Mitra A**, MacIntyre DA, Marchesi JR, Lee YS, Bennett PR, Kyrgiou M. The vaginal microbiota, human papillomavirus  
358 infection and cervical intraepithelial neoplasia: what do we know and where are we going next? *Microbiome*.  
359 2016; 4(1):1–15.
- 360 **Nicolò S**, Tanturli M, Mattiuz G, Antonelli A, Baccani I, Bonaiuto C, Baldi S, Nannini G, Menicatti M, Bartolucci G,  
361 et al. Vaginal lactobacilli and vaginal dysbiosis-associated bacteria differently affect cervical epithelial and  
362 immune homeostasis and anti-viral defenses. *International journal of molecular sciences*. 2021; 22(12):6487.
- 363 **Norenhag J**, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal microbiota, human  
364 papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. *BJOG: An International  
365 Journal of Obstetrics & Gynaecology*. 2020; 127(2):171–180.
- 366 **Okodo M**, Okayama K, Teruya K, Sasagawa T. Uniplex E6/E7 PCR method detecting E6 or E7 genes in 39 human  
367 papillomavirus types. *Journal of Medical Virology*. 2018; 90(5):981–988.
- 368 **Ou YC**, Fu HC, Tseng CW, Wu CH, Tsai CC, Lin H. The influence of probiotics on genital high-risk human papilloma  
369 virus clearance and quality of cervical smear: a randomized placebo-controlled trial. *BMC Women's Health*.  
370 2019; 19(1):1–7.
- 371 **Pal A**, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy.  
372 *Frontiers in microbiology*. 2020; 10:3116.
- 373 **Pedregosa F**, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R,  
374 Dubourg V, et al. Scikit-learn: Machine learning in Python. *the Journal of machine Learning research*. 2011;  
375 12:2825–2830.
- 376 **Quast C**, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. The SILVA ribosomal  
377 RNA gene database project: improved data processing and web-based tools. *Nucleic acids research*. 2012;  
378 41(D1):D590–D596.
- 379 **Robeson MS**, O'Rourke DR, Kaehler BD, Ziemski M, Dillon MR, Foster JT, Bokulich NA. RESCRIPt: Reproducible  
380 sequence taxonomy reference database management. *PLoS computational biology*. 2021; 17(11):e1009581.
- 381 **Sasagawa T**, Inoue M, Inoue H, Yutsudo M, Tanizawa O, Hakura A. Induction of uterine cervical neoplasias in  
382 mice by human papillomavirus type 16 E6/E7 genes. *Cancer research*. 1992; 52(16):4420–4426.
- 383 **Schwameis R**, Ganhoer-Schimboeck J, Hadjari VL, Hefler L, Bergmeister B, Kuessel T, Gittler G, Steindl-  
384 Schoenhuber T, Grimm C. TRICIN: A Phase II Trial on the Efficacy of Topical Trichloroacetic Acid in Patients  
385 with Cervical Intraepithelial Neoplasia. *Cancers*. 2022; 14(23):5991.
- 386 **Usyk M**, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, Gonzalez P, Safaeian M, Schiffman M, Burk RD,  
387 et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. *PLoS pathogens*. 2020;  
388 16(3):e1008376.
- 389 **Willis A**, Bunge J. Estimating diversity via frequency ratios. *Biometrics*. 2015; 71(4):1042–1049.

- 390 **Winer RL**, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: inci-  
391 dence and risk factors in a cohort of female university students. *American journal of epidemiology*. 2003;  
392 157(3):218–226.
- 393 **Yang B**, Wang Y, Qian PY. Sensitivity and correlation of hypervariable regions in 16S rRNA genes in phylogenetic  
394 analysis. *BMC bioinformatics*. 2016; 17(1):1–8.
- 395 **Ziemski M**, Wisanwanichthan T, Bokulich NA, Kaehler BD. Beating naive Bayes at taxonomic classification of  
396 16S rRNA gene sequences. *Frontiers in Microbiology*. 2021; 12:644487.